anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Study will enroll diabetic patients (new and established) meeting the inclusion criteria and who would provide an informed consent to participate in the study. This would include subjects who visit the endocrinology clinic and had either their retina evaluated by a teleophthalmology consult or visited the ophthalmology clinic for an indirect ophthalmoscopic fundus evaluation in the past 3 months. Subjects whose fundus has been recently evaluated in the past 3 months will also be re-called to the endocrinology clinic to get a fundus image captured on the Remidio NM FOP-10 device. Images will be captured by an operator who will be provided training in using the device prior to the study.

Non-mydriatic fundus images are captured using a pre-defined imaging protocol. One disc centered and one macula centred 45 deg image is taken for each eye. The images are then submitted to an AI system for analysis that runs locally on the Remidio FOP. An initial image quality assessment is performed by the AI. If the image is of sufficient quality then the AI will give an output of either 'signs of DR detected' (that would include moderate NPDR, severe NPDR, PDR and/or DME present) or no signs of diabetic retinopathy detected (that would include no DR, mild DR, absence of DME). If the image is of insufficient quality, then the operator makes 2 more attempts using the same imaging protocol. The images that are output as insufficient quality will be noted. All subjects who have provided consent for dilation are then instilled with a single drop of 1% tropicamide solution. After 20 mins, mydriatic 2 field (one disc centered and one macula centered) fundus images are captured and submitted to the AI for analysis along the same lines of non-mydriatic imaging. If the image is of insufficient quality then the operator makes 2 more attempts using the same imaging protocol. The images that are output as insufficient quality will be noted.

De-identified patient data including age, gender, ethnicity and lens status (Cataract grade, pseudophakia, aphakia) along with the final diagnosis made by a certified grader/ophthalmologist during clinical examination/teleophthalmology are retrieved from the NHS database. This DR diagnosis will act as a reference standard against which the AI output will be compared.

Data entry of subjects will be performed by approved trained Site Personnel. The de-identified data is stored onto an electronic data capture system (EDC). Approved Site Personnel will have a user specific log-in name and password to access the electronic data capture (EDC) system in order to enter study data. The principal investigator will ensure that all aspects of the study are complied with. The study will be conducted in accordance with applicable regulatory requirements and established rules for Good Clinical Practice (GCP).
<P>PROBLEM TO BE SOLVED: To provide a W/O type micro-emulsion containing water finely and stably dispersed in various kinds of oils with no need of application of strong mechanical outside force or no need of using a plurality of surfactants or co-surfactants.  <P>SOLUTION: The W/O type micro-emulsion is a W/O type micro-emulsion containing a bio-surfactant. The W/O type micro-emulsion is a micro-emulsion containing a bio-surfactant produced in a large quantity from reproducible resource by microorganism, has a large particle diameter of water droplets dispersed in an oil, and is thermodynamically stable. The W/O type micro-emulsion can be obtained efficiently at a low cost with no need of adding a plurality of surfactants and co-surfactants in large quantities or no need of loading intense mechanical energy. Further, the W/O type micro-emulsion can be used in a wide range of spheres for emulsion fuels, cosmetics such as cleansing oil, medical products and food.  <P>COPYRIGHT: (C)2008,JPO&INPIT
This is a Phase-1 randomized, double-blind, placebo- and active-controlled, parallel group 6 week study to evaluate the effect on the HPA axis of treatment with SKP FlutiForm 250/10 mg HFA pMDI twice daily administered over 6 weeks, FlutiForm 100/10 mg HFA pMDI twice daily administered over 6 weeks and 10 mg prednisone administered over 7 days compared to placebo. All subjects will undergo a Screening Visit to determine eligibility for the study and training on pMDI use. Eligible subjects will meet all of the following criteria: at least 6 month history of asthma, demonstrate an FEV1 of at least ≥ 60 % of predicted normal values at both Screening and Baseline visits, and stable asthma without the use of inhaled steroids for the past month or oral or parenteral corticosteroids for the past three months. All subjects will be admitted to the study site on the morning of Study Day -1 to begin a 24-hour urine collection and undergo Baseline trough PK sampling. On the morning of Study Day 1, subjects will be randomized to one of four treatment groups: SKP FlutiForm 250/10 mg twice daily + placebo capsule for six weeks, SKP FlutiForm 100/10 mg twice daily + placebo capsule for six weeks, Placebo inhaler + placebo capsule for six weeks or Placebo inhaler for six weeks + placebo capsule for 5 weeks followed by one week of 10 mg prednisone QD. After the first dose, subjects will be discharged from the study site to continue dosing at home for 6 weeks. Subjects will be required to record their compliance with their twice daily inhaler dosing and once daily oral medication dosing in a diary. Subjects will also record their predose morning and evening Peak Expiratory Flow Rate (PEFR) in a diary. Clinic visits will occur at Study Days 7, 14 and 35 during which safety assessments (AEs and vital signs) will be made, trough PK samples will be obtained and pMDI training will be continued. Also, subjects will return to the study site in the morning on Study Days 40 to 41 for observed dosing of prednisone or placebo. Subjects will be readmitted to the study site in the morning on Study Day 42 for trough PK sampling, observed dosing of prednisone or placebo and to begin a 24-hour urine collection. A safety follow-up phone call will occur 7 days later.
This invention provides methods and process of identification and producing pure, biologically active compound(s) from Xanthoceras sorbifolia. This invention also provides the composition of the pure compound(s) of interest from Xanthoceras sorbifolia. The purified compounds comprise saponins. The composition can be used for treating cancer, arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud’s syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder, impotence and premature ejaculation; for preventing cerebral aging; for improving memory, cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer’s disease, autism, brain trauma, Parkinson’s disease or other diseases caused by cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud’s syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder. This invention provides compounds comprising a triterpene backbone or Sapogenin, in which the sugar moiety attached to Carbon 3 of the triterpene backbone; an acetyl and/or sugar moiety linkage to Carbon 21 and 22; and angeloyl groups attached to the sugar moiety. These functional groups operatively linked to the triterpene or Sapogenin to form the compound.
Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The complexes of the invention comprise a drug, at least one lipid species, optionally at least one polycation, and at least one targeting factor. The at least one lipid species may comprise a pegylated lipid. The complexes of the invention may provoke lower levels of inflammatory cytokines such as tumor necrosis factor-.alpha. (TNF-.alpha.). The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.
The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.Topics include 1) GBM identity, 2) "HIV 101," 3) HIV/STI testing, 4) alcohol and the body, 5) the role of alcohol in HIV risk, 6) HIV-status disclosure and sexual health communication, 7) finding social supports, and 8) summary. EAC participants will receive five quiz questions after each module, with correct answers in a following screen.
We previously demonstrated that transcutaneous CO2 application promotes muscle fiber-type switching, fracture healing, and osteogenesis by increasing blood flow and angiogenesis. Here, we aimed to investigate the preventive effects of transcutaneous CO2 application on disuse osteoporosis and muscle atrophy in a rat hindlimb suspension model. Eleven-week-old male Sprague-Dawley rats were divided into hindlimb suspension (HS), HS with transcutaneous CO2 application (HSCO2), and control groups. HSCO2 rats were administered transcutaneous 100 % CO2 gas in their bilateral hindlimbs, five times a week for 20 min. After 3 weeks, we harvested the gastrocnemius, femur, and tibia for assessment. Histological analysis revealed a significant decrease in the gastrocnemius myofiber cross-sectional area in HS rats compared to the control rats, whereas HSCO2 rats exhibited a significant increase compared to HS rats. Micro-computed tomography showed significant bone atrophy in the trabecular and cortical bones of the femur in HS rats compared to those of the control rats, whereas significant improvement was noted in HSCO2 rats. Histological analysis of the proximal tibia revealed more marrow adipose tissue in the HS rats than in the control rats. However, in the HSCO2 rats, fewer marrow adipose tissue and osteoclasts were observed. Moreover, HSCO2 rats had more osteoblasts and higher expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and vascular endothelial growth factor (VEGF) than the HS rats. The gastrocnemius and distal femur of HSCO2 rats also exhibited elevated PGC-1α and VEGF expression and upregulation of the myogenesis markers and osteogenesis markers compared to those of HS rats. This treatment effectively prevented disuse osteoporosis and muscle atrophy by promoting local angiogenesis and blood flow. PGC-1α is crucial for promoting this angiogenic pathway. Transcutaneous CO2 application may be a novel preventive procedure for disuse osteoporosis and muscle atrophy, complementing medication and rehabilitation.
Water supplies in many parts of the world contain naturally occurring arsenic. Previous studies have shown that arsenic at high doses can cause cancer of the bladder. The risk at lower doses is unknown. This study is examining the relationship between ingested arsenic and bladder cancer in central Nevada and Kings County, California, two areas where a large percentage of the population was exposed to drinking water containing arsenic at low to moderate levels. Approximately 200 people with bladder cancer and 400 people without bladder cancer will be included. Subjects are interviewed by telephone about past residences, occupations, diet, drinking water consumption, and other lifestyle factors. Arsenic measurements in well water have been collected from the appropriate state agencies and are being matched with residences and drinking water consumption rates to estimate lifetime arsenic exposures for each subject. People with bladder cancer will then be compared to those without to see if people with cancer were more likely to have lived in areas with arsenic in their drinking water.
As many cells throughout the body possess the vitamin D receptor, adequate vitamin D levels may be essential for multiple physiologic functions. In recent years, vitamin D insufficiency has been linked to insulin resistance, inflammation, poor psychological health, obesity, type 2 diabetes, and cardiovascular disease - these are also commonly found in women with Polycystic Ovary syndrome (PCOS). We believe that vitamin D insufficiency contributes to insulin resistance, inflammation, and psychological distress in women with PCOS. These adverse effects may ultimately increase the risk for serious long-term complications in PCOS, including type 2 diabetes and cardiovascular disease. The key objectives of this research study are to determine the effects of vitamin D supplementation on insulin resistance, inflammation, mood and overall well-being in women with PCOS.

The protocol has been modified by adding the following specific aim: To compare vascular function in healthy age and BMI similar matched women to PCOS women pre-treatment. Our hypothesis is that PCOS women will have greater attenuations in retinal vascular reactivity compared to healthy control women, demonstrating poorer endothelial function. We are currently recruiting healthy women who are age and BMI similar to the PCOS women and measure their retinal vascular reactivity for comparisons to the PCOS women's pre-treatment vascular reactivity. These healthy women will only have a baseline visit in which retinal vascular reactivity will be measured. They will not be enrolled in the placebo or Vitamin D randomization process as described above.
The continuous standard-dose 17-β-estradiol group will receive the standard therapy for prevention of osteoporosis. A transdermal patch that releases 50ug/24 hrs of 17-β-estradiol will be administered continuously during the 16 weeks of treatment.
The overall aim of CALERIE Phase 2 is to test the hypothesis that two years of sustained caloric restriction (CR), involving a reduction in energy intake to 75% of baseline (25% CR), in healthy, non-obese men aged 21-50 (inclusive) and women aged 21-47 (inclusive), will result in the same adaptive changes that were observed in a wide variety of animal studies. Particular emphasis is on the adaptive responses thought to be involved in slowing the aging process and protecting against age-related disease processes. Primary outcomes include core body temperature and resting metabolic rate. Secondary outcomes include risk factors for cardiovascular disease, inflammatory markers, immune function, psychological and physical function; oxidative changes in lipids, proteins, and DNA; and, risk factors for age-related conditions such as diabetes and body composition. An important secondary aim is to identify potential adverse effects of CR in humans.

The study will be conducted as a multi-center, parallel-group, randomized, controlled trial (RCT). A sample of 200 participants will be enrolled, and assigned to either the CR intervention or a control group. Control participants will be advised to simply continue their current diets. Participants in both treatment arms will be followed over a period of 24 months. A comprehensive set of evaluations will be performed prior to initiating the intervention, with follow-up evaluations at 1, 3, 6, 9, 12, 18 and 24 months afterwards.
The present invention relates to virus-like nanoparticles for antiviral antibody production. The virus-like nanoparticles for antiviral antibody production, according to an embodiment of the present invention, are implemented by comprising: nanoparticles; and antigenic determinants of target viruses provided on the surface of the nanoparticles. The virus-like nanoparticles for antiviral antibody production are implemented similarly in size to actual viruses, and as the antigenic determinants can be provided at high density, the recognition rate as an antigen which triggers an immune response in a host animal is improved. Thus, the virus-like nanoparticles can more easily immunize the host animal, and is suitable for producing antibodies against a target virus in large quantities at a low cost. In addition, the virus-like nanoparticles are non-toxic and do not harm the host animal into which the nanoparticles are injected. Accordingly, the antibodies finally obtained through the virus-like nanoparticles, according to the present invention, can be applied to a therapeutic agent for treating an infected human body, a detection kit for identifying the infection with a target virus, or a diagnostic method.
BACKGROUND: Mechanical softening of the glial scar region regulates axonal regeneration to impede neurological recovery in central nervous system (CNS) injury. Microglia, a crucial cellular component of the glial scar, facilitate neuronal survival and neurological recovery after spinal cord injury (SCI). However, the critical mechanical characterization of injured spinal cord that harmonizes neuroprotective function of microglia remains poorly understood.
METHODS: Spinal cord tissue stiffness was assessed using atomic force microscopy (AFM) in a mouse model of crush injury. Pharmacological depletion of microglia using PLX5622 was used to explore the effect of microglia on mechanical characterization. Conditional knockout of Fascin-1 in microglia (Fascin-1 CKO) alone or in combination with inhibition of myosin activity was performed to delve into relevant mechanisms of microglia regulating mechanical signal. Immunofluorescence staining was performed to evaluate the related protein levels, inflammatory cells, and neuron survival after SCI. The Basso mouse scale score was calculated to assess functional recovery.
RESULTS: Spinal cord tissue significantly softens after SCI. Microglia depletion or Fascin-1 knockout in microglia limits tissue softening and alters mechanical characterization, which leads to increased tissue pathology and impaired functional recovery. Mechanistically, Fascin-1 inhibits myosin activation to promote microglial migration and control mechanical characterization after SCI.
CONCLUSIONS: We reveal that Fascin-1 limits myosin activity to regulate mechanical characterization after SCI, and this mechanical signal should be considered in future approaches for the treatment of CNS diseases.
Patients received dietary advice for 15 days. Dietary advice consisted of a low fermentation diet which was delivered as a written list of food and beverages that patients should avoid adapted to local habits and an oral explanation by a health professional.
PURPOSE:To produce a superoxide dismutase (SOC), by reacting the SOC with a copolymer containing specific group as constitutional units and having a specific average mol. wt. in an aqueous solution of alkali having pH 7-11. CONSTITUTION:A superoxide dismutase is reacted with a copolymer containing a group such as formula I (R<1> is H or methyl and R<2> is H, Cl, Br or methyl group), group expressed by formula II (R<7> is H, 1-4C alkanol, etc.) and group expressed by formula III as constitutional units and having 800-20,000 average mol. wt. in an aqueous solution having pH 7-11 to provide the SOD derivative. The derivative is expressed by formula IV (SOC is a superoxide dismutase having 1-6 groups excluding one H from amino group; Z is the above-mentioned formula I; X is integer of 1-6).
The invention relates to the field of pharmaceutical preparations, in particular to a polypeptide hydrogel for promoting skin repair and a preparation method and application thereof. The invention provides a self-assembly peptide and also provides a polypeptide hydrogel formed by an aqueous solution of the self-assembly peptide. The invention also provides a method for preparing the polypeptide hydrogel. The invention also provides application of the polypeptide hydrogel in treating diabetic mouse skin injury. The polypeptide hydrogel can promote the healing of the injured skin of the diabetic mouse, the generation of skin appendages, the increase of the positive rate of PCNA cells and the promotion of the accumulation of CD31 positive blood vessels and collagen. The invention also provides the application of the polypeptide hydrogel in-vitro cell 3D culture; wherein, the human keratinocyte cell line HaCaT cells grow spherically in the polypeptide hydrogel, and the PDGF and VEGF expression level of the cells is higher than that of two-dimensional cultured cells.
PROBLEM TO BE SOLVED: To eliminate difficulty for many people in finding a motivation required to maintain a regular exercise program by providing an exercise regimen that involves continuously repetitive motions, such as running, walking and bicycling.SOLUTION: Tracking and monitoring an athletic activity offers individuals with additional motivation to continue such behavior. An individual may track his or her athletic activity by completing goals. These goals may be represented by real-world objects such as food items, landmarks, buildings, statues, other physical structures, toys and the like. Each object may correspond to an athletic activity goal and require an amount of the athletic activity to complete the goal. For example, a donut goal object may correspond to an athletic activity goal of burning 350 calories. The user may progress from one goal object to another one by one.
The present invention relates to an effective component of pilose asiabell root of a single medicinal traditional Chinese medicinal material and a preparation method for the preparation of pilose asiabell root ointment. The present invention is characterized in that pilose asiabell root of a raw material is cut up, and water with a quantity of 7 to 10 times of the pilose asiabell root is added. The pilose asiabell root is decocted for 2 to 3 times, and each time is 2 to 3 hours. The liquid is filtered, filtrate is collected, and two kinds of filtrate are merged, decompressed and concentrated to semifluid. The polysaccharide content of effective components of the pilose asiabell root reaches more than 10%, and simultaneously, the extract of other effective parts is reserved. The method for preparing a preparation of pilose asiabell root ointment has the technical steps that 100 kilograms of medicinal materials of pilose asiabell root are chosen, and pure water is added in the medicinal materials to be decocted for 2 to 3 hours. The liquid is filtered, and filtrate is collected, and is decocted twice. Each time is added with 700kg of water, and each time is boiled for 2 hours. The decoction liquid is filtered, filtrate is collected, and the two kinds of filtrate are merged. The filtrate is decompressed and concentrated to semifluid, and the specific gravity is from 1.31 to 1.34 when measured at a temperature of 80 DEG C to 85 DEG C. The polysaccharide content of the pilose asiabell root in effective components of the pilose asiabell root reaches more than 15%, and the pilose asiabell root ointment can be obtained.
Embodiments are directed towards embodiments for monitoring or predicting user health with respect their use of connected computers, such as, mobile phones, tablets, or the like. Activities associated with a user and a computing device may be monitored to determine activity events. One or more sub-scores may be provided in real time based on metrics provided as input to sub-score models such that the metrics are associated with the activity events. A health score associated with a probability of an occurrence of adverse user outcomes may be provided based on a health model that uses the sub-scores. An analysis engine may compare the health score to other health scores to predict in real time the adverse outcomes. The analysis engine may recommend one or more actions to decrease the probability of the occurrence of the adverse outcomes based on the result.